Proton therapy and concurrent chemotherapy may reduce bone marrow toxicity in advanced lung cancer

Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.

Read the whole article on Physorg

More from Physorg